Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label comparison of migalastat versus enzyme replacement therapy in Fabry disease previously treated with ERT
2010-022636-37Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Dec 2010
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of migalastat in Fabry disease (FD) (2 arms), sponsored by Amicus Therapeutics. Primary endpoint: Change from baseline in iohexol GFR. Started Dec 2010; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2010-022636-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022636-37.